NCT03361410

Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year

Completed Phase 2 Last updated 21 February 2023

What this trial tests

Phase 2 trial testing Grape Powder in Mild Cognitive Impairment in 32 participants. Completed in 15 October 2022.

Timeline

18 November 2017

Primary endpoint
15 October 2022

15 October 2022

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	32
Start date	18 November 2017
Primary completion	15 October 2022
Estimated completion	15 October 2022
Sites	1 location across United States

Drugs / interventions tested

• Grape Powder
• Placebo Powder

Conditions studied

• Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →

Sponsor

University of California, Los Angeles

Who can join

Adults 65 to 85, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Constituents of grapes have been studied for their antioxidant, anti-inflammatory, and anticarcinogenic properties. In the past decade, there has been emerging evidence regarding a potential role for grapes in slowing cognitive decline and other effects of aging. Furthermore, evidence has been obtained in vivo that supplementation with grape seed extract in aged rats improves cognitive performance, and that supplementation with grapes in people having decline in cognition leads to preservation of metabolism in brain regions important to cognitive function over a period of six months. The investigator aims to measure effects of grape intake on cerebral metabolism and neuropsychological performance, and to determine whether initial patterns, and magnitude of change, of cerebral metabolism assessed by positron emission tomography (PET) can serve respectively as a predictor of, and biomarker for, the magnitude of cognitive changes resulting from intake of grapes over a period of at least one year.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Pathological mechanisms and therapeutic strategies for Alzheimer's disease.
   Ju Y, Tam KY. · · 2022 · cited 260× · PMID 34380884 · DOI 10.4103/1673-5374.320970
2. Alzheimer Disease: Recent Updates on Apolipoprotein E and Gut Microbiome Mediation of Oxidative Stress, and Prospective Interventional Agents.
   Botchway BO, Okoye FC, Chen Y, Arthur WE, et al · · 2022 · cited 23× · PMID 35111364 · DOI 10.14336/ad.2021.0616
3. Natural Products from Plants and Algae for Treatment of Alzheimer's Disease: A Review.
   Klose J, Griehl C, Roßner S, Schilling S. · · 2022 · cited 7× · PMID 35625622 · DOI 10.3390/biom12050694
4. Decoding natural products for neuroprotection: Pathway networks and structural insights for drug development.
   Ghosh S, Debnath I, Bhunia S, Nandi S, et al · · 2025 · cited 4× · PMID 41399798 · DOI 10.1016/j.chmed.2025.09.005